Description
LHC-165 is a benzonaphthyridine TLR7 agonist.
Product Unit Size | Cost | Quantity | Stock |
---|
LHC-165 is a benzonaphthyridine TLR7 agonist.
Cas No. | 1258595-14-0 |
---|---|
Purity | ≥99% |
Formula | C29H32F2N3O7P |
Formula Wt. | 603.56 |
IUPAC Name | 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid |
Synonym | LHC165 |
Appearance | Pale yellow powder |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
Info Sheet |
---|
Zawit M, Swami U, Awada H, et al. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med. 2021 Jun;9(12):1038. PMID: 34277838
Endogenous peptide, involved in paracrine and a...
Endogenous opioid peptide derived from the β-c...
FGFR inhibitor.
Synthetic peptide, vasopressin derivative; V2 a...
Alkaloid found in species of Loranthus, Calia, ...
Steroid; glucocorticoid agonist.
TRPA1 antagonist
Trihydroxybenzoic acid glycoside found in Berge...
DPP4 inhibitor.
Renin inhibitor.
Protein translation inhibitor.
Carcinoembryonic antigen epitope.
Recombinant protein containing Treponema pallid...
Anthracycline, DNA intercalator; topoisomerase ...
Estradiol metabolite.
β-lactam; transpeptidase inhibitor.
Peptide, involved in paracrine and autocrine ce...
Endogenous peptide hormone; GnRH agonist.
Trichothecene mycotoxin produced by Fusarium; p...
p110α PI3K and mTOR inhibitor.